Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Series B Preferred stock	Series C Preferred stock	Preferred Stock	Common Stock	Surplus	Unearned ESOP Shares	Accumulated Other Comprehensive Loss	Retained Earnings	Retained Earnings Series B Preferred stock	Retained Earnings Series C Preferred stock
Beginning balance (in shares) at Dec. 31, 2016				123,098	11,362,716
Beginning balance at Dec. 31, 2016	$ 214,376			$ 41,110	$ 1,136	$ 111,166	$ (1,233)	$ (1,010)	$ 63,207
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(11,761)								(11,761)
Dividends on preferred stock		$ (2,880)	$ (362)							$ (2,880)	$ (362)
Dividends on common stock	(2,802)								(2,802)
Conversion of Series C preferred stock to common stock (in shares)				(1,223)	6,791
Conversion of Series C preferred stock to common stock				$ (123)	$ 1	122
Issuance of common stock, net of offering expenses of $683 (in shares)					5,100,034
Issuance of common stock, net of offering expenses of $683	57,151				$ 510	56,641
Restricted stock grant (in shares)					58,090
Restricted stock grant					$ 6	(6)
Vested restricted stock (in shares)					700
Exercise of stock options (in shares)					20,498
Exercise of stock options	266				$ 2	264
ESOP shares released for allocation	296						296
Stock based compensation expense	225					225
Adoption ASU 2018-02								(324)	324
Change in accumulated other comprehensive income/loss	(494)							(494)
Ending balance at Dec. 31, 2017	254,015			$ 40,987	$ 1,655	168,412	(937)	(1,828)	45,726
Ending balance (in shares) at Dec. 31, 2017				121,875	16,548,829
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(27,516)								(27,516)
Dividends on preferred stock		$ (2,880)	$ (359)							$ (2,880)	$ (359)
Dividends on common stock	(662)								(662)
Conversion of Series C preferred stock to common stock (in shares)				(154)	855
Conversion of Series C preferred stock to common stock				$ (15)		15
Restricted stock grant (in shares)					84,998
Restricted stock grant					$ 8	(8)
Restricted stock forfeitures (in shares)					(43,197)
Restricted stock forfeitures					$ (4)	4
Exercise of stock options (in shares)					49,532
Exercise of stock options	643				$ 5	638
ESOP shares released for allocation	127						127
ESOP reversal of unreleased shares	810						810
Stock based compensation expense	50					50
Change in accumulated other comprehensive income/loss	(2,238)							(2,238)
Ending balance at Dec. 31, 2018	$ 221,990			$ 40,972	$ 1,664	$ 169,111	$ 0	$ (4,035)	$ 14,278
Ending balance (in shares) at Dec. 31, 2018				121,721	16,641,017